
Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

Published: August 10th 2021 | Updated:

Published: August 9th 2021 | Updated: